Compare VVX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | TRVI |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2014 | 2019 |
| Metric | VVX | TRVI |
|---|---|---|
| Price | $81.71 | $17.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $69.88 | $21.55 |
| AVG Volume (30 Days) | 649.6K | ★ 2.2M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 126.85 | 31.91 |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $4,480,038,000.00 | N/A |
| Revenue This Year | $7.81 | N/A |
| Revenue Next Year | $5.84 | N/A |
| P/E Ratio | $58.98 | ★ N/A |
| Revenue Growth | ★ 3.65 | N/A |
| 52 Week Low | $50.89 | $6.93 |
| 52 Week High | $93.98 | $20.22 |
| Indicator | VVX | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 51.00 |
| Support Level | $65.02 | $17.46 |
| Resistance Level | $92.89 | $20.19 |
| Average True Range (ATR) | 4.42 | 0.83 |
| MACD | -0.29 | -0.09 |
| Stochastic Oscillator | 38.16 | 44.54 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.